Meeting
2015 Genitourinary Cancers Symposium
Effect of selinexor (KPT-330), a novel oral selective inhibitor of nuclear export (SINE), on tumor suppressors and cell cycle proteins in prostate cancer cells and regression of castration-resistant patient-derived xenograft tumor growth.
Authors
Sankar N. Maity
The University of Texas MD Anderson Cancer Center, Houston, TX
Sankar N. Maity , Guanglin Wu , Jing-Fang Lu , Anh Hoang , Yosef Landesman , Dilara McCauley , Robert Carlson , Tami Rashal , Sharon Shacham , Bradley McIntosh Broom , Keith A. Baggerly , Ana Aparicio , Eleni Efstathiou , John C. Araujo , Christopher Logothetis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Prostate Cancer - Advanced Disease
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 277)
DOI
10.1200/jco.2015.33.7_suppl.277
Abstract #
277
Poster Bd #
D20
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Genomic determinants of sensitivity to bipolar androgen therapy (BAT) in castrate-resistant prostate cancer (CRPC).
First Author: Michael Thomas Schweizer
Poster
2020 ASCO Virtual Scientific Program
Preclinical evaluation of XPO1 inhibition in Wilms tumors.
First Author: Michael Vincent Ortiz
Poster
2018 ASCO Annual Meeting
Preclinical effect of selinexor (KPT-330), a selective inhibitor of nuclear export, in pediatric rhabdoid tumors.
First Author: Lianna Jean Marks
Poster
2023 ASCO Genitourinary Cancers Symposium
Preclinical evaluation of teleglenastat (CB-839) in prostate cancer.
First Author: Elaine T. Lam